(Q26750530)

English

Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent

scientific article

In more languages

Statements

scholarly article

0 references

systematic review

1 reference

based on heuristic

inferred from title

Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent (English)

0 references

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

author name string

Paul S Yamauchi

1

0 references

Robert Bissonnette

2

0 references

Henrique D Teixeira

3

0 references

Wendell C Valdecantos

4

0 references

language of work or name

0 references

publication date

September 2016

0 references

Journal of the American Academy of Dermatology

0 references

75

0 references

612-618.e6

0 references

3

0 references

Infliximab in the treatment of psoriasis in patients previously treated with etanercept

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab treats psoriasis in patients previously treated with etanercept: a case series

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JAAD.2016.02.1221

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.JAAD.2016.02.1221

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26750530&oldid=1639083386"